| Unternehmen / Aktien | News 24 h | News 7 T | Kurs | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 24 | 5 | -4,81 % | ||
| ORUKA THERAPEUTICS | 22 | - | +10,17 % | ||
| LIGAND PHARMACEUTICALS | 13 | 2 | 0,00 % | ||
| SAGIMET BIOSCIENCES | 9 | 1 | +34,40 % | ||
| ANAPTYSBIO | 8 | 2 | +12,53 % | ||
| CORMEDIX | 7 | 10 | +5,39 % | ||
| FULCRUM THERAPEUTICS | 7 | - | -1,66 % | ||
| RELAY THERAPEUTICS | 6 | 3 | -0,86 % | ||
| BIONTECH | 5 | 13 | -3,22 % | ||
| MIRUM PHARMACEUTICALS | 5 | 1 | +0,33 % |
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01:26 | Spyre Therapeutics (SYRE): Favorite Stock of Elite Money Managers | 5 | Insider Monkey | ||
| Mo | Intellia's Data Reveal Tees Up FDA Filing for CRISPR-Based In Vivo Gene-Editing Med | 2 | MedCity News | ||
| Mo | Crinetics erhält EU-Zulassung für Akromegalie-Medikament Palsonify | 5 | Investing.com Deutsch | ||
| Mo | Taysha legt präklinische Daten zur Gentherapie für das Rett-Syndrom vor | 1 | Investing.com Deutsch | ||
| Mo | Taysha to present preclinical data on Rett syndrome gene therapy | 1 | Investing.com | ||
| Mo | Relay Therapeutics: Oppenheimer hebt Kursziel nach Daten zu Dreifachkombination an | 1 | Investing.com Deutsch | ||
| Mo | Crinetics receives EU approval for acromegaly drug Palsonify | 1 | Investing.com | ||
| Mo | Oppenheimer raises Relay Therapeutics stock price target on triplet data | 4 | Investing.com | ||
| Mo | Taysha Gene Therapies, Inc.: Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| Mo | Starke Studienergebnisse: Clear Street erhöht Kursziel für Oruka Therapeutics auf 131 US-Dollar | 3 | Investing.com Deutsch | ||
| Mo | Crinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY (Paltusotine) for the Treatment of Acromegaly in Adults | 3 | GlobeNewswire (USA) | ||
| Mo | Lexeo Therapeutics Announces Multiple Presentations at the 29th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting | 1 | GlobeNewswire (USA) | ||
| Mo | Aclaris veröffentlicht am Dienstag Studiendaten zu ATI-052 und Update zu ATI-2138 | 2 | Investing.com Deutsch | ||
| Mo | Clear Street raises Oruka Therapeutics price target on trial results | 3 | Investing.com | ||
| Mo | Aclaris to release ATI-052 trial data, ATI-2138 update Tuesday | 1 | Investing.com | ||
| Mo | Cabaletta Bio Announces Multiple Upcoming Presentations, Including Data on Rese-cel without Preconditioning and Rese-cel with Automated Manufacturing, at the ASGCT 2026 Annual Meeting | 1 | GlobeNewswire (USA) | ||
| Mo | Aclaris Therapeutics, Inc.: Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026 | 1 | GlobeNewswire (USA) | ||
| Mo | Editas Medicine stellt präklinische Daten zur LDL-senkenden Therapie EDIT-401 vor | 2 | Investing.com Deutsch | ||
| Mo | Sana Biotechnology stellt präklinische Daten zu CAR-T-Therapiekandidat auf Fachtagung vor | 1 | Investing.com Deutsch | ||
| Mo | Sana Biotechnology präsentiert im Mai präklinische Daten zur CAR-T-Zelltherapie | 1 | Investing.com Deutsch |